دورية أكاديمية
Glutathione levels are associated with methotrexate resistance in acute lymphoblastic leukemia cell lines.
| العنوان: | Glutathione levels are associated with methotrexate resistance in acute lymphoblastic leukemia cell lines. |
|---|---|
| المؤلفون: | Canevarolo RR; Centro de Pesquisa Boldrini, Centro Infantil Boldrini, Campinas, SP, Brazil., Melo CPS; Centro de Pesquisa Boldrini, Centro Infantil Boldrini, Campinas, SP, Brazil., Cury NM; Centro de Pesquisa Boldrini, Centro Infantil Boldrini, Campinas, SP, Brazil., Artico LL; Centro de Pesquisa Boldrini, Centro Infantil Boldrini, Campinas, SP, Brazil., Corrêa JR; Centro de Pesquisa Boldrini, Centro Infantil Boldrini, Campinas, SP, Brazil., Tonhasca Lau Y; Centro de Pesquisa Boldrini, Centro Infantil Boldrini, Campinas, SP, Brazil., Mariano SS; Centro de Pesquisa Boldrini, Centro Infantil Boldrini, Campinas, SP, Brazil., Sudalagunta PR; Department of Cancer Physiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States., Brandalise SR; Centro de Pesquisa Boldrini, Centro Infantil Boldrini, Campinas, SP, Brazil., Zeri ACM; Brazilian Biosciences National Laboratory (LNBio), Brazilian Center for Research in Energy and Materials (CNPEM), Campinas, SP, Brazil., Yunes JA; Centro de Pesquisa Boldrini, Centro Infantil Boldrini, Campinas, SP, Brazil.; Medical Genetics Department, Faculty of Medical Sciences, State University of Campinas, Campinas, SP, Brazil. |
| المصدر: | Frontiers in oncology [Front Oncol] 2022 Dec 01; Vol. 12, pp. 1032336. Date of Electronic Publication: 2022 Dec 01 (Print Publication: 2022). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مستخلص: | Introduction: Methotrexate (MTX), a folic acid antagonist and nucleotide synthesis inhibitor, is a cornerstone drug used against acute lymphoblastic leukemia (ALL), but its mechanism of action and resistance continues to be unraveled even after decades of clinical use. Methods: To better understand the mechanisms of this drug, we accessed the intracellular metabolic content of 13 ALL cell lines treated with MTX by 1H-NMR, and correlated metabolome data with cell proliferation and gene expression. Further, we validated these findings by inhibiting the cellular antioxidant system of the cells in vitro and in vivo in the presence of MTX. Results: MTX altered the concentration of 31 out of 70 metabolites analyzed, suggesting inhibition of the glycine cleavage system, the pentose phosphate pathway, purine and pyrimidine synthesis, phospholipid metabolism, and bile acid uptake. We found that glutathione (GSH) levels were associated with MTX resistance in both treated and untreated cells, suggesting a new constitutive metabolic-based mechanism of resistance to the drug. Gene expression analyses showed that eight genes involved in GSH metabolism were correlated to GSH concentrations, 2 of which (gamma-glutamyltransferase 1 [GGT1] and thioredoxin reductase 3 [TXNRD3]) were also correlated to MTX resistance. Gene set enrichment analysis (GSEA) confirmed the association between GSH metabolism and MTX resistance. Pharmacological inhibition or stimulation of the main antioxidant systems of the cell, GSH and thioredoxin, confirmed their importance in MTX resistance. Arsenic trioxide (ATO), a thioredoxin inhibitor used against acute promyelocytic leukemia, potentiated MTX cytotoxicity in vitro in some of the ALL cell lines tested. Likewise, the ATO+MTX combination decreased tumor burden and extended the survival of NOD scid gamma (NSG) mice transplanted with patient-derived ALL xenograft, but only in one of four ALLs tested. Conclusion: Altogether, our results show that the cellular antioxidant defense systems contribute to leukemia resistance to MTX, and targeting these pathways, especially the thioredoxin antioxidant system, may be a promising strategy for resensitizing ALL to MTX. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Renatino Canevarolo, Pereira de Souza Melo, Moreno Cury, Luiz Artico, Ronchi Corrêa, Tonhasca Lau, Sousa Mariano, Reddy Sudalagunta, Regina Brandalise, Carolina de Mattos Zeri and Andrés Yunes.) |
| التعليقات: | Erratum in: Front Oncol. 2023 Mar 28;13:1190120. (PMID: 37056334) |
| References: | PLoS One. 2012;7(3):e33894. (PMID: 22479469) Blood. 2012 Aug 9;120(6):1165-74. (PMID: 22730540) Blood. 2002 Jun 1;99(11):4100-8. (PMID: 12010813) Curr Protoc Bioinformatics. 2016 Sep 07;55:14.10.1-14.10.91. (PMID: 27603023) Pharmazie. 2011 Jun;66(6):440-4. (PMID: 21699084) J Hematol Oncol. 2015 May 29;8:61. (PMID: 26022503) Sci Rep. 2021 Feb 10;11(1):3490. (PMID: 33568707) J Clin Oncol. 2012 May 10;30(14):1663-9. (PMID: 22412151) Leuk Lymphoma. 2014 Jul;55(7):1591-5. (PMID: 24090503) PLoS One. 2013 May 13;8(5):e63276. (PMID: 23675469) Trends Pharmacol Sci. 2017 Sep;38(9):794-808. (PMID: 28648527) N Engl J Med. 2013 Jul 11;369(2):111-21. (PMID: 23841729) Redox Biol. 2015;4:127-35. (PMID: 25560241) Am J Hematol. 1987 Sep;26(1):67-75. (PMID: 2888307) Expert Opin Drug Metab Toxicol. 2014 May;10(5):699-719. (PMID: 24673379) Blood. 1999 Nov 1;94(9):3121-8. (PMID: 10556198) Acta Haematol. 1978;59(2):65-72. (PMID: 24319) Free Radic Biol Med. 1999 Nov;27(9-10):922-35. (PMID: 10569625) Clin Transl Sci. 2020 Jan;13(1):137-146. (PMID: 31651077) Naunyn Schmiedebergs Arch Pharmacol. 1999 May;359(5):411-9. (PMID: 10498292) Blood. 1995 Jan 15;85(2):500-9. (PMID: 7812005) Rinsho Ketsueki. 2016;57(10):2022-2028. (PMID: 27795510) Nat Commun. 2021 Dec 14;12(1):7268. (PMID: 34907175) Cancer Res. 2014 Jan 1;74(1):56-67. (PMID: 24310398) J Clin Invest. 2016 May 2;126(5):1630-9. (PMID: 27135880) Haematologica. 2006 Aug;91(8):1105-8. (PMID: 16870552) Arthritis Rheum. 2006 May;54(5):1366-77. (PMID: 16645965) Cancer Res. 1984 Aug;44(8):3190-5. (PMID: 6204743) Clin Exp Rheumatol. 2000 Nov-Dec;18(6):691-8. (PMID: 11138330) PLoS One. 2009;4(1):e4251. (PMID: 19158949) J Proteome Res. 2017 Apr 7;16(4):1773-1783. (PMID: 28244322) Exp Hematol. 2015 Feb;43(2):89-99. (PMID: 25448488) Nat Commun. 2016 Apr 29;7:11457. (PMID: 27126896) Oncologist. 2016 Dec;21(12):1471-1482. (PMID: 27496039) Cancer Cell. 2015 Feb 9;27(2):211-22. (PMID: 25620030) Toxicol Lett. 2000 Nov 20;117(3):129-37. (PMID: 11087978) Nature. 2011 Jul 13;475(7355):231-4. (PMID: 21753854) J Biol Chem. 2020 Mar 6;295(10):2890-2899. (PMID: 32019866) Oncotarget. 2017 May 30;8(22):35728-35742. (PMID: 28415723) Free Radic Biol Med. 2012 Jan 15;52(2):436-43. (PMID: 22100505) J Investig Med. 2012 Oct;60(7):1064-7. (PMID: 22914600) Blood Adv. 2021 Oct 12;5(19):3776-3788. (PMID: 34464977) Nat Genet. 2011 Sep 04;43(10):932-9. (PMID: 21892159) J Biol Chem. 1989 Feb 25;264(6):3524-8. (PMID: 2914962) Leuk Res. 2012 Jul;36(7):841-5. (PMID: 22534100) J Clin Oncol. 2017 Feb 20;35(6):605-612. (PMID: 27400939) Cancer Res. 2002 Jun 1;62(11):3144-50. (PMID: 12036927) Nature. 2018 Jul;559(7715):632-636. (PMID: 29995852) Leukemia. 2000 Mar;14(3):467-73. (PMID: 10720143) Blood. 2010 Mar 4;115(9):1690-6. (PMID: 20018913) J Proteome Res. 2014 Dec 5;13(12):6033-45. (PMID: 25382592) J Biol Chem. 1989 Sep 25;264(27):16261-7. (PMID: 2777791) Life Sci. 2000;66(23):2297-307. (PMID: 10855951) Leuk Res Rep. 2017 Mar 09;7:29-32. (PMID: 28462082) Sci Rep. 2020 May 12;10(1):7838. (PMID: 32398698) Cochrane Database Syst Rev. 2013 Mar 28;(3):CD009594. (PMID: 23543579) JCI Insight. 2021 Dec 22;6(24):. (PMID: 34793338) EBioMedicine. 2020 Apr;54:102716. (PMID: 32268267) Clin Chem Lab Med. 2013 Mar 1;51(3):571-8. (PMID: 23241677) Br J Haematol. 2003 Jan;120(1):80-8. (PMID: 12492580) Biochem Pharmacol. 1992 Jun 23;43(12):2527-33. (PMID: 1378736) Free Radic Biol Med. 2001 Dec 1;31(11):1287-312. (PMID: 11728801) J Biol Chem. 2015 Jan 23;290(4):2244-50. (PMID: 25480787) Antioxid Redox Signal. 2017 Jul 10;27(2):106-114. (PMID: 27733046) J Biol Chem. 1990 May 25;265(15):8470-8. (PMID: 2341391) J Bioenerg Biomembr. 2001 Dec;33(6):493-501. (PMID: 11804191) Arthritis Rheum. 2004 May;50(5):1370-82. (PMID: 15146406) Cancer Chemother Pharmacol. 2002 Nov;50(5):419-28. (PMID: 12439601) NMR Biomed. 2002 Feb;15(1):37-44. (PMID: 11840551) J Clin Invest. 2020 Dec 1;130(12):6600-6615. (PMID: 33164984) Blood. 2003 Dec 15;102(13):4493-8. (PMID: 12816874) J Clin Invest. 2005 Jan;115(1):110-7. (PMID: 15630450) PLoS Med. 2008 Apr 15;5(4):e83. (PMID: 18416598) Open Biol. 2015 Sep;5(9):150093. (PMID: 26333836) Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12288-93. (PMID: 17640917) J Vis Exp. 2015 Jul 15;(101):e53070. (PMID: 26274375) PLoS One. 2015 Jun 17;10(6):e0127558. (PMID: 26083398) PLoS One. 2012;7(10):e48175. (PMID: 23118946) Oncol Rep. 2014 Sep;32(3):1057-63. (PMID: 24969544) J Pharmacol Exp Ther. 1984 Dec;231(3):660-4. (PMID: 6502520) Nat Cancer. 2020 Nov;1(11):1113-1127. (PMID: 33796864) Leukemia. 2012 Mar;26(3):433-42. (PMID: 21904379) Mol Pharmacol. 1997 May;51(5):825-32. (PMID: 9145921) Mol Med. 2012 May 09;18:423-32. (PMID: 22193356) Cancer Genomics Proteomics. 2022 Jan-Feb;19(1):79-93. (PMID: 34949661) Br J Pharmacol. 2003 Feb;138(3):501-11. (PMID: 12569075) Cancer Res. 2017 Jun 15;77(12):3336-3351. (PMID: 28400475) Front Pharmacol. 2013 Mar 14;4:28. (PMID: 23504227) Adv Enzyme Regul. 1993;33:207-18. (PMID: 7689289) Mutagenesis. 2015 May;30(3):421-30. (PMID: 25681790) Cancers (Basel). 2014 Sep 05;6(3):1769-92. (PMID: 25198391) J Clin Invest. 2018 Dec 3;128(12):5517-5530. (PMID: 30260324) Anticancer Drugs. 2007 Apr;18(4):389-404. (PMID: 17351391) J Clin Invest. 1996 Jan 1;97(1):73-80. (PMID: 8550853) Cell Biochem Funct. 1998 Dec;16(4):283-93. (PMID: 9857491) Cancer Metab. 2015 May 28;3:6. (PMID: 26023330) Oncotarget. 2015 May 30;6(15):13105-18. (PMID: 25869207) Oncol Lett. 2019 Sep;18(3):3115-3127. (PMID: 31452789) Front Oncol. 2015 Jul 28;5:167. (PMID: 26284193) Cancer Cell. 2019 May 13;35(5):752-766.e9. (PMID: 31085176) Blood. 2002 Nov 15;100(10):3832-4. (PMID: 12411325) Pharmacogenomics J. 2012 Oct;12(5):386-94. (PMID: 21606946) Cancer Res. 1993 May 15;53(10 Suppl):2227-30. (PMID: 7683570) Cancer Res. 1992 Mar 15;52(6):1434-8. (PMID: 1371715) Mol Pharmacol. 2005 Feb;67(2):545-57. (PMID: 15537867) |
| فهرسة مساهمة: | Keywords: acute lymphoblastic leukemia; arsenic trioxide; drug resistance; glutathione; metabolomics; methotrexate; thioredoxin reductase |
| تواريخ الأحداث: | Date Created: 20221219 Latest Revision: 20230430 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9751399 |
| DOI: | 10.3389/fonc.2022.1032336 |
| PMID: | 36531023 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2022.1032336 |